Cantor Fitzgerald Thinks Aimmune Therapeutics’ Stock is Going to Recover


In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on Aimmune Therapeutics (AIMT), with a price target of $64. The company’s shares closed yesterday at $23.42, close to its 52-week low of $21.47.

Duncan wrote:

“. We reiterate our Overweight rating and 12-month PT of $64/share on AIMT after attending Aimmune’s Analyst & Investor Event. We believe AR101 has a high regulatory and commercial PoS based on P3 PALISADE data, and we expect a BLA filing by Track & Break Through designations resulting in a possible PDUFA date early in 2H19. We also anticipate an MAA in ~mid-2019 should the results of ARTEMIS be positive.”

According to TipRanks.com, Duncan is a 1-star analyst with an average return of -1.2% and a 42.0% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.

Currently, the analyst consensus on Aimmune Therapeutics is a Strong Buy with an average price target of $59.50, a 154.1% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Buy rating on the stock with a $40 price target.

.

See today’s analyst top recommended stocks >>

Based on Aimmune Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $51.7 million. In comparison, last year the company had a GAAP net loss of $31.79 million.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Read More on AIMT:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts